SITE008-0402

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2023-07-17

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-03 (study day 42); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-03 (study day 42); relationship: not assessed

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-07 (study day 46); relationship: N

severe serious assessed

Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-09-27 (study day 66); relationship: not assessed; serious criteria: hospitalization

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-10-18 (study day 87); relationship: N

severe assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-10-22 (study day 91); relationship: not assessed

Data queries

No data queries.